Piperazine, compound with phosphoric acid

Repeated dose toxicity: dermal

Administrative data

Endpoint:

repeated dose toxicity: dermal

Remarks:

other: subchronic

Type of information:

(Q)SAR

Adequacy of study:

supporting study

Reliability:

2 (reliable with restrictions)

Justification for type of information:

QSAR prediction: migrated from IUCLID 5.6

Data source

Reference

Reference Type:

other: Prediction data

Title:

[R]: 552 mg/kg bw/day (nominal); Estimation for NOAEL for CAS 1951-97-9

Author:

Sustainability Support Services (Europe) AB

Year:

2013

Bibliographic source:

QSAR Toolbox version 3.1

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

other: ;OECD Guideline 411 (Subchronic Dermal Toxicity: 90-Day Study)

GLP compliance:

no

Test material

Test material information

Constituent 1

Reference substance name:

Piperazine, compound with phosphoric acid

EC Number:

217-775-8

EC Name:

Piperazine, compound with phosphoric acid

Cas Number:

1951-97-9

Molecular formula:

C4H10N2.xH3O4P

IUPAC Name:

phosphoric acid; piperazine

Details on test material:

SMILES:C1CNCCN1_O=P(O)(O)O

Test animals

Species:

rabbit

Strain:

other: New Zealand White

Sex:

male/female

Administration / exposure

Type of coverage:

other: occlusive

Vehicle:

water

Duration of treatment / exposure:

90 days

Frequency of treatment:

5 days per week for 13 weeks

Doses / concentrations

Remarks:

Doses / Concentrations:
0, 10, 50, 150mg/kg
Basis:
other: nominal per unit body weight

No. of animals per sex per dose:

10

Control animals:

yes, concurrent vehicle

Details on study design:

- Dose selection rationale: Not specified but highest dose likely to be based on tolerance to irritation.

Results and discussion

Effect levels

Dose descriptor:

NOAEL

Effect level:

551.5 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

male/female

Target system / organ toxicity

Critical effects observed:

not specified

Any other information on results incl. tables

The prediction was based on dataset comprised from the following descriptors: NOAEL
Estimation method: Takes average value from the 6 nearest neighbours
Domain  logical expression:Result: In Domain

((("a" and ("b" and ( not "c") )  )  and "d" )  and ("e" and "f" )  )

Domain logical expression index: "a"

Referential boundary: The target chemical should be classified as Low (Class I) by Toxic hazard classification by Cramer (original)

Domain logical expression index: "b"

Referential boundary: The target chemical should be classified as Inclusion rules not met by Skin irritation/corrosion Inclusion rules by BfR

Domain logical expression index: "c"

Referential boundary: The target chemical should be classified as Aromatic amines by Skin irritation/corrosion Inclusion rules by BfR

Domain logical expression index: "d"

Referential boundary: The target chemical should be classified as Bioavailable by Lipinski Rule Oasis

Domain logical expression index: "e"

Parametric boundary:The target chemical should have a value of log Kow which is >= -3.81

Domain logical expression index: "f"

Parametric boundary:The target chemical should have a value of log Kow which is <= 2.2

Applicant's summary and conclusion

Conclusions:

Repeated dose toxicity NOAEL (No observed adverse effect level) of piperazine, compound with phosphoric acid to rabbit by the dermal route was estimated at a dose concentration of 551.5 mg/kg bw/day.
On the basis of this NOAEL value it is concluded that the test substance is not toxic to rabbit by the dermal route below the above mentioned dose.

Executive summary:

Repeated dose toxicity NOAEL (No observed adverse effect level) of piperazine, compound with phosphoric acid to rabbit by the dermal route was estimated at a dose concentration of 551.5 mg/kg bw/day.

On the basis of this NOAEL value it is concluded that the test substance is not toxic to rabbit by the dermal route below the above mentioned dose.